Xtant Medical Holdings, Inc. (XTNT) Stock Forecast
XTNT analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 2 analysts
- Price target
- $1.03 average of analyst targets
- Upside to target
- +256.3% from the latest close
- Next earnings
- November 9, 2026
- 52-week range
- $0.29 – $0.92
XTNT analyst ratings
2 analystsNumber of analysts at each rating.
XTNT price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
XTNT earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.02 | −$0.03 | −$0.02 | $0.01 | −269.1% | 3 |
| Current fiscal year (2026) | −$0.08 | −$0.08 | −$0.08 | $0.04 | −317.6% | 1 |
| Next fiscal year (2027) | −$0.03 | −$0.06 | −$0.01 | −$0.08 | +62.5% | 3 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
XTNT revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $25.5M | $23.9M | $26.6M | −23.4% | 3 |
| Current fiscal year (2026) | $99.4M | $97.8M | $100.5M | −25.8% | 3 |
| Next fiscal year (2027) | $110.2M | $109.6M | $110.6M | +10.8% | 3 |
XTNT EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
XTNT revenue: reported and forecast
XTNT EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.01 | −$0.01 | −$0.01 | −$0.02 | −$0.02 | +133.0% | 0 up · 1 down |
| Current fiscal year (2026) | −$0.08 | −$0.08 | −$0.08 | $0.00 | −$0.08 | 0.0% | 0 up · 1 down |
| Next fiscal year (2027) | −$0.01 | −$0.01 | −$0.01 | −$0.04 | −$0.03 | +500.0% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
XTNT earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; XTNT beat in 8 of 12.
What analysts expect from XTNT
2 analysts cover Xtant Medical; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $1.03, 256.3% above the latest close of $0.29. Analysts expect earnings of −$0.08 per share for 2026, −317.6% from a year earlier. For 2027 the average estimate is −$0.03 per share on revenue of $110.2 million. Xtant Medical beat the EPS estimate in 8 of the last 12 quarters.
Related: XTNT income statement, XTNT key metrics, XTNT chart. See the XTNT stock overview for the latest quote and news.
XTNT forecast FAQ
What is Xtant Medical's price target?
The average analyst price target for Xtant Medical is $1.03, 256.3% above the latest close of $0.29.
Is Xtant Medical a buy, hold or sell?
Of 2 analysts covering Xtant Medical, 2 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Xtant Medical's EPS forecast?
Analysts forecast −$0.08 per share for 2026 (range −$0.08 to −$0.08); for 2027 the estimate is −$0.03.
What is Xtant Medical's revenue forecast?
The average revenue estimate for 2026 is $99.4 million, growth of −25.8%; for 2027 it is $110.2 million.
When does Xtant Medical report earnings?
Xtant Medical is expected to report results for the quarter ending September 30, 2026 on November 9, 2026.
Does Xtant Medical usually beat earnings estimates?
Xtant Medical reported EPS at or above the analyst estimate in 8 of the last 12 quarters.